Why the study?
The incidence and prevalence of heart failure are rising in The Netherlands, but there is room for improvement in guideline adherence for diagnosis and treatment.
Underuse of ACE-I and beta-blockers persists in Dutch HF care; reinforces need for better guideline implementation across primary and specialist settings.
In The Netherlands, the incidence and prevalence of heart failure are rising as is the case in most other European countries. Overall, there are 200,000 patients with heart failure in The Netherlands and around 25,000 hospitalisations annually with a discharge diagnosis of heart failure. Most of these patients are managed in primary care, often together with a cardiologist. There is an active guideline program in different professional organisations (e.g. general practitioners, cardiologists) and in 2002 a collaborative multidisciplinary guideline for management of chronic heart failure was developed. However, there is clearly room for improvement in the adherence to these guidelines both with regard to the diagnosis and the treatment of HF patients. For example, ACE-I and beta-blockers are still under-prescribed. In particular, the more severely ill patients seem to be under treated. At present, general practitioners and cardiologists differ in their views on heart failure, resulting in differences in diagnosis and management. In addition to the multidisciplinary guidelines, several other initiatives have been developed to improve outcomes in these patients, such as rapid access clinics and outpatient heart failure clinics.
No takes yet. Share an insight, caveat, or question.
Jaarsma et al. (2005) conducted a review in Heart failure. Heart failure affects approximately 200,000 patients in the Netherlands, with management showing under-prescription of ACE inhibitors and beta-blockers despite multidisciplinary guidelines.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: